McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
IPO Year:
Exchange: NYSE
Website: mckesson.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $630.00 | Neutral | Mizuho |
| 11/7/2024 | $531.00 → $688.00 | Neutral → Outperform | Robert W. Baird |
| 9/24/2024 | $603.00 → $531.00 | Outperform → Neutral | Robert W. Baird |
| 9/5/2024 | $670.00 → $665.00 | Outperform | Leerink Partners |
| 8/8/2024 | $540.00 → $570.00 | Neutral | Mizuho |
| 2/26/2024 | $600.00 | Outperform | Leerink Partners |
| 1/3/2024 | $537.00 | Overweight | Barclays |
| 12/14/2023 | $502.00 | Equal Weight | Wells Fargo |
| 3/31/2023 | $420.00 | Buy | Citigroup |
| 8/22/2022 | Overweight | Morgan Stanley |
McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Co
McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an
McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph
McKesson Corporation (NYSE:MCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. "This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation," said Brian Tyler, chief executive officer. "We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders." About McKesson Corporation McKesson Corporat
McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph
McKesson Corporation (NYSE:MCK) has released its fiscal 2024 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Tuesday, May 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on July 1, 2024, to stockholders of record on June 3, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and rea
McKesson Corporation (NYSE:MCK) will release its fourth quarter and full year fiscal 2024 financial results after market close on Tuesday, May 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care pro
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00
Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously
Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously
Leerink Partners reiterated coverage of McKesson with a rating of Outperform and set a new price target of $665.00 from $670.00 previously
Mizuho reiterated coverage of McKesson with a rating of Neutral and set a new price target of $570.00 from $540.00 previously
Leerink Partners initiated coverage of McKesson with a rating of Outperform and set a new price target of $600.00
Barclays initiated coverage of McKesson with a rating of Overweight and set a new price target of $537.00
Wells Fargo initiated coverage of McKesson with a rating of Equal Weight and set a new price target of $502.00
Citigroup initiated coverage of McKesson with a rating of Buy and set a new price target of $420.00
Morgan Stanley resumed coverage of McKesson with a rating of Overweight
10-Q - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
424B5 - MCKESSON CORP (0000927653) (Filer)
FWP - MCKESSON CORP (0000927653) (Subject)
8-K - MCKESSON CORP (0000927653) (Filer)
424B3 - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
10-Q - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th
CALGARY, AB, Jan. 25, 2022 /CNW/ - Comprehensive Healthcare Systems Inc. (TSXV:CHS) (the "Company" or "CHS"), an industry leader in Healthcare Benefits Administration software and services, is pleased to announce the appointment of Chris Cosgrove as the Company's new President and Chief Executive Officer ("CEO") and to its board of directors effective February 1, 2022. Mr. Cosgrove has 25 years of management and leadership experience in the healthcare technology industry and will replace CHS founder, Dr. Hassan Mohaideen, who will continue in his role as Chairman of the board of directors (the "Board") and be appointed Chief Medical Officer of the Company. "With a proven track record of lea
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
McKesson Corporation (NYSE:MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms. Additional details related to the divestiture can be found on the company's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biop
McKesson Corporation (NYSE:MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Co
McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an
Believes Nano's Ongoing Value Destruction, Worst-In-Class Corporate Governance and Misallocation of Corporate Resources Warrants Urgent Change in Company's Boardroom Murchinson's Nominees Would Bring Independent Perspectives and Relevant Experience to Restore Shareholders' Confidence in Leadership, Establish Appropriate Capital Allocation Processes, Hold Management Accountable and Oversee Strategy Development and Implementation Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.1% of the outstanding shares of Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano" or the "Company"), today annou
McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph
McKesson Corporation (NYSE:MCK) announced today that it has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. In line with McKesson Corporation's enterprise strategy, this transaction enables McKesson to further focus and prioritize investments to grow its oncology and biopharma services platforms. McKesson Corporation remains fully committed to and confident in the strength of our Canadian distribution and biopharma businesses, delivering solutions to ensure the delivery of better health outcomes. "This transaction marks an important milestone aligned to our enterprise strategy, advancing our strate
Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil
McKesson Corporation (NYSE:MCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. "This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation," said Brian Tyler, chief executive officer. "We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders." About McKesson Corporation McKesson Corporat